This study aims to evaluate the safety and effectiveness of different combinations of new medicines in individuals with Non-Small Cell Lung Cancer. This type of cancer is a common form of lung cancer that starts in the cells located in the outer parts of the lungs. The study focuses on patients whose cancer is locally advanced, meaning it has grown into nearby tissues, or metastatic, which means the cancer has spread to other parts of the body.

Participants may receive combinations of several medications, including the experimental drug rilvegostomig and the medication ramucirumab. Other medicines that may be part of the treatment plan include mycophenolate mofetil and infliximab. These medications are administered through different methods, such as oral pills taken by mouth or IV infusion, which is a process where medicine is delivered directly into a vein through a tube.

During the study, the way the body processes these drugs and how the immune system reacts to them will be monitored. The research will look at how well the treatments work by observing changes in the size of tumors and how long the cancer remains stable. Researchers will also track any adverse events, which are unwanted or harmful side effects that may occur during treatment.